Analyzing Ayala Pharmaceuticals (NASDAQ:ADXS) & Aadi Bioscience (NASDAQ:AADI)

Risk & Volatility

Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Earnings & Valuation

This table compares Ayala Pharmaceuticals and Aadi Bioscience”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24 million	11.05	-$48.07 million	($5.02)	-0.12
Aadi Bioscience	$25.07 million	3.54	-$65.76 million	($2.35)	-1.53

Ayala Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ayala Pharmaceuticals and Aadi Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Insider and Institutional Ownership

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Ayala Pharmaceuticals beats Aadi Bioscience on 7 of the 11 factors compared between the two stocks.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.